Target Organs and Levels of Evidence for TR-374
Toxicology and Carcinogenesis Studies of Glycidol (CASRN 556-52-5) In F344/N Rats and B6C3F1 Mice (Gavage Studies)
Chemical (Study Title)
CASRN |
Peer Review Date |
Route/Exposure Levels |
Study Laboratory |
Glycidol
556-52-5 |
06/27/1989 |
Gavage
R: 0,38,75, M: 0,25,50 MG/KG/50 PER GROUP |
Papanicolaou Research Institute |
Levels of Evidence
Male Rats: Clear Evidence
| Type |
Organ/Tissue (Lesion) |
| Neoplastic Lesions |
- Mesothelium (Abdominal Cavity/Tunica Vaginalis): MESOTHELIOMA 3/50 34/50 39/50
- Mammary Gland: FIBROADENOMA 3/50 8/50 7/50
- Brain: GLIOMA 0/50 5/50 6/50
- Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50
- Large Intestines: ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50
- Skin: SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50
- Zymbal Gland: CARCINOMA 1/50 3/50 6/50
- Thyroid Gland Follicular Cell: ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50
|
| Non-Neoplastic Lesions |
- FORESTOMACH: HYPERKERATOSIS 3/50 13/50 15/50; DYSPLASIA, EPITHELIAL 0/50 10/50 8/50
- SPLEEN: FIBROSIS 13/50 34/50 28/50
|
Female Rats: Clear Evidence
| Type |
Organ/Tissue (Lesion) |
| Neoplastic Lesions |
- Mammary Gland: FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50
- Brain: GLIOMA 0/50 4/50 4/50
- Oral Cavity: SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50
- Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50
- Clitoral Gland: ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50
- Thyroid Gland Follicular Cell: ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49
- Hematopoietic System: LEUKEMIA 13/50 14/50 20/50
|
| May Have Been Related |
- Glandular Stomach: FIBROSARCOMA 0/50 0/50 2/50
|
| Non-Neoplastic Lesions |
- FORESTOMACH: HYPERKERATOSIS 1/50 16/50 13/50; DYSPLASIA, EPITHELIAL 0/50 12/50 10/50
- SPLEEN: FIBROSIS 3/50 14/49 20/50
|
Male Mice: Clear Evidence
| Type |
Organ/Tissue (Lesion) |
| Neoplastic Lesions |
- Harderian Gland: ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50
- Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50
- Skin: SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50
- Liver: ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50
- Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50
|
| May Have Been Related |
- Urinary Bladder: CARCINOMA 0/50 1/50 1/50
- Epididymis: SARCOMA 0/50 0/50 2/50
|
| Non-Neoplastic Lesions |
- FORESTOMACH: HYPERKERATOSIS 3/50 8/50 7/50
- PREPUTIAL GLAND: CYST 1/50 0/50 7/50
- KIDNEY: CYST 4/50 11/50 9/50
|
Female Mice: Clear Evidence
| Type |
Organ/Tissue (Lesion) |
| Neoplastic Lesions |
- Harderian Gland: ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50
- Mammary Gland: ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50
- Uterus/Cervix: CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50
- Subcutaneous Tissue: SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50
- Skin: SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50
|
| Non-Neoplastic Lesions |
- FORESTOMACH: HYPERKERATOSIS 5/50 3/50 11/50
|
